Skip to main content
OpenTrials
Completed

NCT Number: NCT02423642

Immunomodulation Effect of Regional Citrate Anticoagulation in Acute Kidney Injury Requiring Continuous Renal Replacement Therapy

The purpose of this study is to study the effect of anticoagulation in immune response with Acute Kidney Injury (AKI) undergoing Continuous Renal Replacement Therapy (CRRT).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Kidney Injury Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Male Urogenital Diseases Renal Insufficiency Urogenital Diseases Urologic Diseases

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Sasipha Tachaboon

Bangkok, Pathumwan, 10330, Thailand

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Systemic inflammatory response syndrome; SIRS > or = 2 meets definition
  • Patients with acute kidney injury in the intensive care ward.
  • Requiring continuous renal replacement therapy.

Exclusion criteria

  • Pregnancy
  • Cirrhosis
  • End stage renal disease
  • HIV infection
  • Serum creatinine in male > 2 mg/dl and female > 1.5 mg/dl
  • Bleeding

Treatment and study plan

Continuous renal replacement therapy with regional citrate anticoagulation

Procedure

CRRT with anticoagulant : regional citrate anticoagulation

Filter : AQUAMAX™ (Edwards Lifesciences)

Other names: Continuous veno-venous hemofiltration

Continuous renal replacement therapy with no anticoagulation or heparin

Procedure

CRRT with any anticoagulant : no anticoagulation or heparin Filter : AQUAMAX™ (Edwards Lifesciences)

Other names: Continuous veno-venous hemofiltration

Primary outcomes

  1. Functions of inflammatory cells

    Time frame: 24 hours

    CD11b expression on PMN and HLA-DR expression on monocyte

  2. Regulation of inflammatory reactions and and opsonization in microorganisms

    Time frame: 24 hours

    C3a and C5a

  3. Activity of acute phase protein during acute inflammation

    Time frame: 24 hours

    PAI-1

Secondary outcomes

  1. survival rate

    Time frame: 28 days

  2. length of ICU stay

    Time frame: 28 days

Sponsors and collaborators

Lead sponsor

Chulalongkorn University

Other

Registry information

Important dates

Study start
2013
Primary completion
2014
Study completion
2014
First posted
Apr 22, 2015
Registry last updated
Mar 5, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.